TY  - JOUR
AU  - Jendrišek, Gorana
AU  - Nikolić, Aleksandra
AU  - Dragičević, Sandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1512
AB  - Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited.
PB  - Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac
T2  - Kragujevac Journal of Science
T1  - Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast
EP  - 125
IS  - 44
SP  - 115
DO  - 10.5937/KgJSci2244115J
ER  - 

@article{
author = "Jendrišek, Gorana and Nikolić, Aleksandra and Dragičević, Sandra",
year = "2022",
abstract = "Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited.",
publisher = "Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac",
journal = "Kragujevac Journal of Science",
title = "Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast",
pages = "125-115",
number = "44",
doi = "10.5937/KgJSci2244115J"
}

Jendrišek, G., Nikolić, A.,& Dragičević, S.. (2022). Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast. in Kragujevac Journal of Science
Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac.(44), 115-125.
https://doi.org/10.5937/KgJSci2244115J

Jendrišek G, Nikolić A, Dragičević S. Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast. in Kragujevac Journal of Science. 2022;(44):115-125.
doi:10.5937/KgJSci2244115J .

Jendrišek, Gorana, Nikolić, Aleksandra, Dragičević, Sandra, "Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast" in Kragujevac Journal of Science, no. 44 (2022):115-125,
https://doi.org/10.5937/KgJSci2244115J . .